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Abstract 
The global pharmaceutical industry is a multibillion dollar, knowledge-driven sub-sector; where 
firms‟ innovation and competitiveness depend greatly on external knowledge. The firm‟s ability 
to recognize, acquire and utilize external knowledge for commercial ends depends on its 
absorptive capacity. Information on the capability of Nigerian pharmaceutical firms to identify, 
assimilate and exploit external knowledge is scarce. This study therefore examined the external 
knowledge sources, absorptive capacity and innovation in Nigeria‟s pharmaceutical industry. A 
purposive sampling of key players comprising MD/CEOs and Chairman/Captains of industry in 
5 out of 8 listed pharmaceutical firms and 3 out of 6 industry associations was conducted in 
2013. Information was elicited using questionnaires and semi –structured interview guide. The 
study found that pharmaceutical firms in Nigeria invested 0.2 to 15 % of their annual sales on 
R&D. The external knowledge sources for the industry were basically through 
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seminars/conferences, internet, customers and suppliers of input. Others included journal 
publications, technical reports, training/skill acquisition, workshops and the Pharmaceutical 
Group meetings. Qualitative assessment of the absorptive capacity of firms in the subsector 
revealed a medium-to-high level rating. The major determinants of absorptive capacity of the 
firms included experience, informal interactions, training and educational qualification of staff. 
Pharmaceutical innovation was majorly in the area of new product and new process 
developments of generic drugs. No new drug moiety development was recorded in the subsector. 
The major technology acquisition strategies utilized for new product and process development 
were in-house R&D, tapping tacit knowledge of staff, and sourcing knowledge from other firms 
in the industry. Strategic partnership was deployed by foreign-owned and multinational firms as 
knowledge acquisition strategies for drug discovery and delivery. 
 














 Pharmaceutical industry with its high research intensity of about 22% in the OECD 
countries (OECD, 1998) invests heavily on research for the development of new drugs.  
Engagement in in-house Research and Development (R&D) activities notwithstanding, industrial 
firms still depend on external sources of knowledge.  External knowledge could be derived from a 
firm‟s own industry, other industries and research institutions (Schmidt, 2005).  It is important for 
the firms to develop capacity to effectively acquire and utilise the knowledge for commericial 
purposes.  The ability of firms to exploit external knowledge is therefore critical to their 
innovativeness and consequently their competitiveness in the global market.  Absorptive capacity 
is explained as the ability of a firm to evaluate and utilize outside knowledge, which is largely a 
function of the level of prior related knowledge Cohen and Levinthal (1990).   Firms endowed 
with higher levels of absorptive capacity will be able to extract greater benefits from similar 
stocks of external knowledge, and therefore outperform rivals in their innovation activity. 
 UNESCO (1992) reported that one of the main causes of weak demand and low 
absorptive capacities in the industrial sector in developing countries is a great lack of 
information, resulting from insufficient technical personnel in this sector.  Learning is a key 
input in the development of absorptive capacity both at the national and firm levels.  Absorptive 
capacity of a firm measures its ability to successfully utilize the ideas embodied in existing 
scientific knowledge and technologies, and translate them into new products and processes.  
Mytelka (2001) opined that absorptive capacity of a firm depends heavily upon the level of 
education and training; by extension a company‟s absorptive capacity similarly would depend 
upon the level of education and training of its personnel.  Therefore, any company that fails to 
build capabilities that would enable it exploit new knowledge would fall behind others.  Using 
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new technologies efficiently requires creating additional absorptive capacity, while a continuous 
effort has to be made to keep up with technical change (UNCTAD, 2005).    
Brief Profile of Nigeria's Pharmaceutical sub-Sector 
The Pharmaceutical industry is multibillion dollar industry – global spending on 
prescription drugs was US$954 in 2011 while the global pharmaceutical industry is estimated to 
reach US$1.1 trillion by 2014 (TMS Health, 2008). There are about 128 local drug 
manufacturers in Nigeria, which represent between 60- 70% of the total pharmaceutical 
manufacturing companies in the West Africa subregion (UNIDO, 2011). The pharmaceutical 
manufacturing sub-sector has an aggregate investment of over N300 billion and employs over 
600,000 people. Between 2000 and 2008, the sub-sector received foreign direct investment of 
about US$1.5bn. The domestic pharmacy market was worth about US$ 600million  in 2009 and 
was projected to grow substantially at about 12% annually to reach US$ 717 million by 2011 
(UNIDO, 2011). The estimated market for prescription ethical pharmaceuticals is US$ 500 
million and that for over the counter (OTC) pharmaceuticals about US$ 900 million. The 
Pharmaceutical Manufacturing Group of the Manufacturing Association of Nigeria (PMG-MAN) 
estimates the market for biological products to be worth US$ 100 million according to (UNIDO, 
2011) report on Nigeria's Pharmaceutical sector profile. Out of the 61 companies registered as 
active members of the Pharmaceutical Manufacturing Group in 2012 only eight (8) are listed on 
the Nigerian Stock Exchange. These attributes were major considerations in purposively 
selecting the subsector for an assessment of the external knowledge sources, absorptive capacity 
and pharmaceutical innovation. 
In an earlier study on pharmaceutical subsector, Oyewale (2010) reported that Nigerian 
Pharmaceutical industry has higher interactions with universities and research institutes than 
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other industries.  The sustainability of the interactions would depend on the ability of the firms to 
utilize the research outputs of the institutions.  What could be responsible for the weak 
interactions of the pharmaceutical firms with the knowledge institutions?  This study investigated 
the external sources of knowledge that Nigerian Pharmaceutical firms are using and their 
absorptive capacities in acquiring and utilizing the knowledge for their productive activities and 
innovation.  
The paper provides information on external knowledge sources for pharmaceutical 
innovation in Nigeria, the absorptive capacity and its determinants. The paper concludes with a 
short summary and suggests policy options. 
 
2.0 STATE-OF-THE-ART 
2.1 External knowledge 
External knowledge is knowledge external to the firm. It is the outcome of a series of 
processes such as information generation, information dissemination and information 
interpretation (Sinkula 1994). Firms leverage on external knowledge as a key tool for 
maximizing competitive advantage and achieving robust innovative performance.  Several 
theoretical and empirical studies (Schmidt, 2005; Lane and Koker, 2006; Vega-Jurado et al., 
2008; Liao, 2009) examining the relationship between knowledge and firm performance affirmed 
that the higher the level of knowledge acquired or accumulated, the greater the level of firm 
performance.  Moenaert et al. (1990) and Nonaka (1991) emphasized the critical importance of 
knowledge to sustainable competitive advantage of the firm in view of uncertainties pervading 
the business environment. B Uncertainties arise from emerging competition, new technologies, 
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rapidly changing consumer preferences, social values and demographics.  Firms are constrained 
by uncertainties to make changes in their core practices or risk failure or decline.   
Moenaert et al. (1990) submitted that the innovation process is defined by "consumer 
uncertainty", "technological uncertainty"  "competitor uncertainty", and "resource uncertainty". 
The four elements constitute an "innovation uncertainty" or "capability gap" at the organisational 
level (Welsch et al., 2002). Gaps in the firm's current knowledge base and the information 
required to develop and commercialize a new product/service give rise to uncertainties.  
Researchers are of the view that the acquisition of new knowledge by an organisation is critical 
for filling the capability gap, increasing the research knowledge base, maintaining the 
distinctiveness of products/services and reducing the level of innovation uncertainty. The 
requisite capability gap-filling knowledge must be valuable, rare, imperfectly imitable and 
without a substitute.  To innovate and perform significantly in the milieu of environmental 
uncertainties, firms must develop capacities and competencies in the acquisition, intra-firm 
dissemination and organizational adaptation of external knowledge (Welsch et al., 2002). In 
Pederson et al.'s view, a firm needs to constantly source or acquire new knowledge in order to 
renew capabilities, innovate, and guard against technological obsolescence and competitive 
imitation (Pederson et al., 2002). 
Acquisition of external knowledge is obtainable from external knowledge resources or 
through cooperation with external agents, such as consumers, suppliers, competitors, 
universities, technology institutes, research institutions and consultants (Czarnitzki and Wastyn, 
2009).  A study of the impact of external knowledge on manufacturing firms observed that new 
product and process development conducted in conjunction with external customers and 
suppliers was positively related to expected market performance (Andersson et al., 2002). In the 
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area of pharmaceutical research, Henderson and Cockburn (1994) reported that the ability to 
encourage and maintain an extensive flow of information across the boundaries of the firm is 
important to the productivity of drug discovery. 
  
 2.2  Absorptive Capacity 
Absorptive capacity is defined as a firm‟s ability to recognize the value of new external 
information, assimilate it and apply it to commercial ends. Zahra and George (2002) expounded 
this subject further by suggesting that absorptive capacity is a dynamic capability (embedded in a 
firm‟s routines and processes that promotes organizational change and evolution), comprising 
potential absorptive capacity (PACAP, i.e. knowledge acquisition and assimilation) and realized 
absorptive capacity (RACAP, i.e. knowledge transformation and exploitation). The construct is 
predicated on several and diverse antecedents (including knowledge stocks, knowledge flows 
and organisational routines), components, outcomes and definitions. Several studies (see for 
example, Cohen and Levinthal, 1989, 1990, 1994; Zahra and George, 2002; Van Den Bosch et 
al., 2003; Schmidt, 2005; Lane and Koker, 2006; Vega-Jurado et al., 2008) have identified the 
process and develop the concepts that link external knowledge flows to firm performance. This 
process is moderated by a firm‟s absorptive capacity. Absorptive capacity enables the firm to 
effectively acquire and utilize external knowledge, which, in turn, affects the firm's ability to 
innovate, adapt to its changing environment and be competitive. In this regard, higher level 
absorptive capacity is reported to increase the firm‟s ability to use more basic (as opposed to 
applied) external knowledge while the firm's absorptive capacity is greatly influenced by the 
nature of external knowledge (i.e. its complexity and applicability) (Vega-Jurago et al., 2008). 
Absorptive capacity gives the firm the ability for pro-action and competence- building instead of 
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reacting to the industry's dynamism (Abdelkader, 2004). Absorptive capacity is useful in 
analyzing diverse, significant and organizational phenomena (Zahra and George, 2002), ranging 
from technology transfer among nations to the efficiency of strategic international alliances. The 
relevance of absorptive capacity has also been extended to  the organizational level, where it is 
used to analyse innovation processes and the effect of organisational learning on creation of 
sustainable competitive advantage (Vega-Jurado et al., 2008). Indeed, Cohen and Levinthal 
(1990) affirmed that it is imperative for a firm to develop its absorptive capacity in order to be 
innovative. 
 
2.3 Absorptive Capacity and Pharmaceutical Innovation 
Pharmaceutical firms focus on a variety of business drivers that help them gain 
competitive advantage and remain profitable. They build absorptive capacity by investing in 
R&D and marketing (Cohen and Levinthal, 1990). It is established that pharmaceutical 
innovation is driven by scientific knowledge (Cohen and Levinthal, 1990; Cockburn, 2004; 
Hassanlou, 2007). Research and Development (R&D) underpin new drug discovery, generates 
technical knowledge and capabilities that enable drug development. The challenges of meeting 
global health needs, in the face of international competition, have compelled pharmaceutical 
firms commitment to enhancing productivity through R&D in order to meet patients‟ demands 
for safe and effective drugs. Pharmaceutical industry therefore invests substantially on R&D to 
the tune of an average 15-20 percent of sales revenue (Hassanlou, 2007).  In advanced countries 
context, pharmaceutical firms perform continuous R&D to develop and maintain core knowledge 
and capabilities (Stone and Flamm, 2003) and also depend on external sources of knowledge. 
This has influenced the scale of public and firms‟ R&D investments and returns in these 
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countries. The scenario is different in developing countries, where pharmaceutical firms R&D 
capability is limited and R&D investment poor. Many firms are therefore relying on external 
knowledge sources, especially from the universities and research institutes, for their innovative 
activities. However, information on the capability of firms in Nigeria‟s pharmaceutical sector to 
identify, assimilate and exploit external knowledge is scarce.  
  An earlier study carried out by our group on “Academia-Industry Interactions in 
Nigeria Pharmaceutical Innovation System” reported workshop participation, staff 
exchange/fellowship programmes, consultancy and knowledge flow to be the predominant 
channels of interactions (Siyanbola et al., 2012). However, the intensity of interactions with 
firms was limited to only 20% of pharmaceutical researchers from universities and 7% from 
research institutes while only 16% of firms surveyed had interactions with the researchers. This 
poor statistics was attributed to the mutually expressed limited awareness of R&D activities 
being carried out by researchers and firm‟s R&D personnel. The weak interactions and lack of 
awareness could have contributed to the poor innovation performance of the sector with the 
attendant costly, heavy reliance on large scale importation of essential drugs to meet local 
demands. What is the level of absorptive capacity and its effect on firm‟s innovation in this 
sector? This paper therefore examined the absorptive capacity of firms in Nigeria‟s 
pharmaceutical industry for R&D output (new knowledge) from the universities and public 
research institutes (URIs).  
 
2.4 Determinants of Firms’ Absorptive Capacity 
The firm absorptive capacity is determined by a set of factors: R&D activities (including 
measuring the ratio of R&D expenditure and sales volume); related prior knowledge and 
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individual‟s skills; the  nature of external knowledge (complexity and applicability); the nature 
of the competitive environment (whether stable or turbulent); organizational structure and human 
resource management practices (including  the quality and efficiency of internal mechanisms for 
fostering communication and relationships among staff) (Schmidit, 2005; Vega- Jurado, 2008), 
number of patents and publications, usages of patents (Liao, 2009). Studies show that R&D 
expenditure plays a role in building absorptive capacity (Cohen and Levinthal, 1989) and a dual 
role in the innovation process of firms: building absorptive capacity & generating new 
knowledge and innovations. R&D-related measures and approaches have been used to model 
absorptive capacity at the firm level. These include: R&D intensity (R&D expenditure/total 
sales), level of R&D investment, continuous R&D activities and existence of an R&D laboratory, 
related prior knowledge and individuals‟ skills; organization's strategic posture and links with the 
environment (networks) constitute other factors influencing absorptive capacity. Absorptive 
capacity is path-dependent because experience and prior knowledge facilitate the use of new 
knowledge. The cumulative nature of knowledge has also been related to employees‟ level of 
education, another determinant of absorptive capacity. It is observed that the more education and 
training an employee receives, the higher his or her individual ability to assimilate and use new 
knowledge will be. As firms‟ absorptive capacities depend on those of their employees, the 
general level of education, experience and training their employees have, has a positive influence 
on firms‟ level of absorptive capacity. 
 
3.0 METHODOLOGY 
A purposive sampling of key players in 5 out of 8 listed firms on the Nigerian Stock 
Exchange and 3 out of 6 industry associations in the pharmaceutical industry was conducted in 
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2013. Information was elicited using questionnaires and semi –structured interview guide. 
Respondents included Chief Executive Officers of the firms and Chairmen of Board of Fellows 
of Pharmacists, Nigerian Association of Industrial Pharmacists and Nigerian Representatives of 
Overseas Pharmaceutical Manufacturers from industry associations. A qualitative assessment of 
the data retrieved was then used to assess external knowledge sources, absorptive capacity and 
innovation in the pharmaceutical sector. 
 
4.0 FINDINGS AND INTERPRETATION 
4.1 Profile of Pharmaceutical firms  
A profile of the firms surveyed showed that 2 firms were indigenously-owned, 1 was 
foreign-owned while 2 were multinationals. These firms realized an average annual sales ranging 
from N450 million to N4.5 billion. The firms‟ years of operation, staff strength and 
qualifications are shown in Table 1. The data indicate that the foreign and multinational firms 












Table 1: Staff Qualification and Years in Operation of Pharmaceutical firms surveyed. 
 Indigenous Foreign Multinational % of Total 













10.67 9.98 6.89 1.55 29.09 
Others 7.22 44.75 3.44 5.16 60.58 
 
Total 20.65 58.18 12.91 8.26 100 
 
















The average staff strength in the indigenous firms was 120- , foreign-owned firm, 338- and 
multinationals, 377- members. The foreign and multinational firms also have more staff with 
master‟s degrees than the indigenous firms. In terms of staff quality, the data reveal that the 
highest academic qualification in the sub sector was a Masters‟ degree, which represents about 
10 % of the work force. A significant number (61%) of the staff had other professional 
qualifications such as MBA, ACCA, etc. The lack of staff with PhD degree might have limited 
pharmaceutical firms‟ absorptive capacity for external knowledge and reduced their capacity for 
innovation since the number of staff with PhDs significantly influences the level of innovation a 






4.2 External Knowledge Sources 
In terms of sourcing for external knowledge to support production activities and address 
industry challenges, all the firms surveyed depended on experienced industry professionals as 
primary knowledge sources. The respondents also admitted to obtaining external 
knowledge/information from the internet, seminars/conferences, customers and suppliers of 
input. In addition, the industry managers claimed to have formal and informal interactions with 
universities & research institutes and other firms in the industry at the organizational and 
individual levels. In order of preference, the industry executives often contacted other firms and 
industry professionals for external knowledge before considering the academia.  Lack of 
relevance to addressing industry problems and high cost implication of knowledge from the 
academia were adduced for the secondary status given to sourcing for knowledge from academic 
sources. Common to the indigenous and foreign firms was their reliance on „other Business 
Associates‟ for external knowledge. This data corroborates previous studies which identified 
„other Business Associates‟ as a crucial source of knowledge that can result in open innovation 
(Egbetokun et al., 2012). Specifically, the foreign and multinational firms acknowledged that 
they obtained additional information from journals/other publications, technical reports, 
trainings/skill acquisition & development workshops and Pharmaceutical Manufacturing Group 
meetings.  
 
4.3 Absorptive Capacity 
            A qualitative assessment/perception of staff absorptive capacity by CEOs, captains of 
industry and industry professionals indicated that indigenous firms‟ exhibited medium level 
absorptive capacity while foreign and multinational firms displayed relatively high level 
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absorptive capacity. This is strongly supported with the respondents‟ claims of the availability of 
in-house R&D facilities, R&D personnel staff strength of 13 with an average of 9 years‟ work 
experience.  
All the firms reported that they engaged their staff in active training both locally and 
foreign on a regular basis; the industry can therefore be regarded as knowledge- driven.  
R&D investment of the pharmaceutical firms surveyed was in the range of 0.2 to 15 % of annual 
sales. Comparatively, this range is substantially lower than the R&D investments of 15-20 
percent of sales revenue committed to R&D in developed countries (Hassanlou, 2007). 
4.4   Pharmaceutical Innovation 
The firms claimed innovation in new product and new process developments. In addition, 
all the firms reported to have developed a range of 1 to 4 new products and 4 new processes each 
in the last three years. Furthermore, the foreign firm reported innovation achievement in drug 
discovery in addition to new process and new drug developments while one of the multinationals 
of the firms achieved innovation in drug delivery. Evidences from oral interviews supported that 
R&D activities of Pharmaceutical companies were limited to new product and process 
developments starting from existing generic formulations. These developments involved 

















4.4.1.  Operational Technology Acquisition Strategies used by Pharmaceutical Firms 
in Nigeria 
 
The surveyed firms in the industry achieved innovation in different facets of drug 
production through the adoption of diverse technology acquisition strategies for the different 
operational aspects of drug production. In the development of new products and processes, the 
technology acquisition strategies utilized by all the firms are tapping tacit knowledge of staff, in-
house R&D, and sourcing knowledge from other firms in the Industry (Table 3). The strategy 
adopted for drug discovery and drug delivery by the firms was strategic partnership. In addition, 
Technology transfer was observed to have an enormous impact on the firms‟ business activities 
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Table 3: New Technology Acquisition Strategies Adopted by Pharmaceutical Firms in  
                Nigeria 
 
4.5            Conclusion and Policy Recommendations 
4.5.1         Conclusion 
The study observed that the firms in the Pharmaceutical sector preferred to seek 
knowledge from other firms in the industry before conatacting the University and Research 
Institutes. The main sources of external knowledge were the Internet, seminar/conferences, 
customers and suppliers of input. The foreign-owned firm and the multinationals – who engaged 
in drug discovery and drug delivery – further obtained external knowledge from patent 
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documents/records, journals/other publications, training/skills development workshops and the 
Pharmaceutical Manufacturing Group meetings.  
The Pharmaceutical sector was characterised by medium-to-high level absorptive 
capacity with experience, informal interactions, training and qualification of staff as the major 
determinants of absorptive capacity. R&D was not a major determinant of absorptive capacity in 
the sector. The R&D and Innovation capabilities were mainly in the area of new product and 
process development, especially in excipient development and generic drug production. 
The major technology acquisition strategies utilized in the sector for new product and 
process development were obtained from in-house R&D, tapping tacit knowledge of staff, 
sourcing knowledge from other firms in the industry. Strategic partnerships were the main 
technology acquisition strategies utilized by foreign-owned and multinational firms in drug 
discovery and drug delivery. 
 
4.5.2 Policy Recommendations  
The pharmaceutical sector has capabilities in the development of new products and processes 
from existing generic formulations. Thus, it is recommended that: 
i. Government should develop the political will to protect the sector by regulating the 
importation of manufactured drugs into the country. This will enable the industry to 
expand to meet domestic pharmaceutical drug demand.  
ii. Government should strengthen the capability of firms to source for and use external 
knowledge for the development of the industry. 
iii. Government should provide necessary infrastructure to enable pharmaceutical firms 
acquire capabilities in drug discovery and drug delivery. 
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iv. Government should foster robust interactions between the pharmaceutical firms, 
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